Clinical Trials Logo

Clinical Trial Summary

This is a randomized phase II multi-institution prospective open label study in which up to 90 subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer who previously received treatment with chemotherapy with FOLFIRINOX or FOLFIRINOX-like regimen will be enrolled into one of two arms:

A: NPC-1C with gemcitabine and nab-paclitaxel or B: gemcitabine and nab-paclitaxel


Clinical Trial Description

During Part 1 of the study, the safe and tolerable dose of NPC-1C in combination with Gemcitabine will be determined. Upon completion of the phase I study up to 90 patients be randomized to one of two arms:

A: Patients will receive NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV nab-paclitaxel (125 mg/m2 as a 30 minute infusion, maximum infusion time not to exceed 40 minutes) followed by gemcitabine (1000 mg/m2 as a 30 minute infusion) for 3 consecutive weeks (on Day 1, 7 and 15 ) followed by a week of rest (for a 28 day cycle).

OR B: Patients will receive on Day 1, 7 and 15 nab-paclitaxel (125 mg/m2 as a 30 minute infusion, maximum infusion time not to exceed 40 minutes) followed by gemcitabine (1000 mg/m2 as a 30 minute infusion) for 3 consecutive weeks (on Day 1, 7 and 15). NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV 30 minutes following the completion of the gemcitabine on days 1 and 15 of the 28 day cycle. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01834235
Study type Interventional
Source Precision Biologics, Inc
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date April 2013
Completion date December 2019

See also
  Status Clinical Trial Phase
Recruiting NCT06388967 - Pancreatic Cancer Detection Consortium
Recruiting NCT03977233 - Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Phase 2
Recruiting NCT05006131 - Pancreatic Cancer Screening for At-risk Individuals
Completed NCT04002128 - Tracheal Colonization and Outcome After Major Abdominal Cancer Surgery N/A
Recruiting NCT03854110 - Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine Phase 1
Recruiting NCT04136522 - Usefulness of the Artery First Approach in Pancreatic Cancer Surgery N/A
Completed NCT03042442 - Relation Between Cachexia, Diabetes and periNeural Invasion in PANcreatic Cancer- Biomarkers Substudy
Completed NCT03152487 - Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis N/A